Form 4: Benitec Biopharma CEO Granted 2.31 Million Stock Options

Benitec Biopharma's CEO, Jerel A. Banks, has been granted 2.31 million stock options that will vest quarterly starting March 31, 2025.

Summary

• Benitec Biopharma Inc. has granted its Chief Executive Officer, Jerel A. Banks, 2,310,000 stock options.
• These options were granted on December 9, 2024, at an exercise price of $12.18 per share.
• The stock options will vest in 16 substantially equal quarterly installments, beginning on March 31, 2025.
• The options expire on December 9, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. The vesting schedule is also a positive sign of long-term commitment.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term performance and commitment from the CEO.

Risks

• The value of the stock options is dependent on the future performance of Benitec Biopharma's stock price.
• If the stock price does not increase above the exercise price of $12.18, the options will have no value.

Future Outlook

The stock options will vest over a four-year period, incentivizing the CEO to focus on long-term value creation for the company.

Industry Context

Granting stock options to executives is a common practice in the biotechnology industry to align management's interests with those of shareholders and incentivize performance.

Comparison to Industry Standards

• Stock option grants are a standard form of executive compensation in the biotech industry, often used to attract and retain talent.
• The vesting schedule of 16 quarterly installments is a typical approach to ensure long-term commitment from the executive.
• The exercise price of $12.18 will be compared to the current market price of the stock to determine the value of the options.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the CEO's interests with the company's long-term success.
• Employees may see this as a sign of stability and commitment from the leadership.

Key Dates

Keywords

stock options, CEO, Benitec Biopharma, equity compensation, vesting, executive compensation